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Essentials:  
- Subclinical thyroid dysfunction (SCTD) has been related to hypercoagulability.  
- We studied its association with recurrent venous thromboembolism (rVTE). 
- Subclinical hyperthyroidism, but not -hypothyroidism, may be associated with lower rVTE 
risk. 
- SCTD is not associated with mortality/differences in thrombophilic biomarkers. 
 
Summary: 
Background: Venous thromboembolism (VTE) and subclinical thyroid dysfunction (SCTD) are both 
common in elderly patients. SCTD has been related to a hypercoagulable state and increased 
thromboembolic risk. However, prospective data on the relationship between SCTD and VTE are 
lacking.  
Objectives: To investigate the relationship between SCTD and recurrent VTE (rVTE), all-cause 
mortality, and thrombophilic biomarkers. 
Patients: Elderly participants with VTE.  
Methods: In a prospective multicenter cohort, thyroid hormones and thrombophilic biomarkers were 
measured 1 year after acute VTE, as both may be influenced by acute thrombosis. We defined 
subclinical hypothyroidism (SHypo) as elevated thyroid stimulating hormone levels (TSH=4.50-19.99 
mIU/l), and subclinical hyperthyroidism (SHyper) as TSH<0.45, both with normal free thyroxine 
levels. Outcomes were incidence of rVTE and overall mortality during follow-up starting after the 1-
year blood sampling. 
Results: Of 561 participants (58% with anticoagulation), 6% had SHypo and 5% SHyper. After 20.8 
months of mean follow-up, 9% developed rVTE and 10% died. rVTE incidence rate was 7.2 (95% 
confidence interval:2.7–19.2) per 100 patient-years in SHypo, 0.0 (0.0-7.6) in SHyper and 5.9 (4.4–
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7.8) in euthyroid participants. In multivariate analyses, the sub-hazard ratio [SHR] for rVTE was 0.00 
(0.00-0.58) in SHyper and 1.50 (0.52–4.34) in SHypo compared to euthyroids, without increased 
thrombophilic biomarkers. SHyper (HR 0.80,0.23–2.81) and SHypo (HR 0.99,0.30–3.29) were not 
associated with mortality.  
Conclusion: In elderly patients, SHyper may be associated with lower rVTE risks. SHypo showed a 
non-statistically significant pattern of an association with rVTE, without increased mortality or 
differences in thrombophilic biomarkers. 
 
Introduction 
Acute venous thromboembolism (VTE), defined as deep vein thrombosis (DVT) or pulmonary 
embolism (PE), is a major health problem. In 2004, approximately 370,000 disease-related deaths 
were reported in a study population from six European countries [1] with an all-cause mortality rate of 
9.9% in the first month after an index VTE in older adults [2]. VTE is mainly a disease of the elderly 
[3] with an incidence between 2.8 and 4.1 cases per 1000 person-years in patients older than 65 years 
[4], leading to important financial and health care issues [5]. VTE may have an increased mortality 
rate with rising age, as shown among 14,721 hospitalized patients with PE [6] with a relative risk 
(RR) of 8.48 for death (95% confidence interval [CI] 4.03-17.90) in patients older than 80 years 
compared to patients below 50 years. Recurrent VTE (rVTE) occurs frequently in up to 4.9 cases per 
100 patients-years [7] with an increasing incidence in the elderly [8]. 
Similar to thromboembolic events, subclinical thyroid dysfunction (SCTD) is a common condition in 
this population with a higher prevalence upon increasing age [9]. The prevalence of subclinical 
hypothyroidism (SHypo) reaches up to 10% in the elderly population, while subclinical 
hyperthyroidism (SHyper) is a less common condition with a prevalence between 0.7 and 3.2% [10], 
and 4.6% in those ≥ 80 years [11]. Several case-control studies reported an increased thrombophilic 
risk profile in patients with overt and subclinical hyperthyroidism (SHyper) by enhancing a 
hypercoagulable and hypofibrinolytic state due to elevated levels of factor VIII (FVIII), factor IX 
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(FIX), von Willebrand factor (vWF:Ag), fibrinogen, and plasminogen activator inhibitor (PAI-1) [12, 
13]. Evidence suggests that hypothyroidism may have a biphasic effect on fibrinolysis, depending on 
disease severity [14, 15]. For instance, a prospective study on 76 middle-aged women found an 
increased fibrinolytic activity in severe hypothyroidism, while patients with moderate hypothyroidism 
(thyroid stimulating hormone [TSH] 10-50 mIU/l) vs. euthyroids may be subject to an increased 
thrombophilic risk mediated by a decreased fibrinolytic activity with lower D-dimer levels, higher 
alpha(2)-antiplasmin activities, and higher levels of tissue plasminogen activator (t-PA) and PAI-1. 
Similarly, patients with SHypo had increased FVII activity [16, 17], high-sensitive C-reactive protein 
(hs-CRP) [18], PAI-1, fibrinogen, and reduced plasma levels of antithrombin (AT) [17] compared to 
healthy controls, all potentially contributing to a thrombophilic state. SHypo has been associated with 
an increased risk of coronary heart disease and mortality [19], whereas the impact of SCTD on the 
development of VTE remains unclear. A cross-sectional study including 150 patients with or without 
VTE found a higher prevalence of SHypo in patients with unprovoked VTE compared to euthyroids 
(Odds’ Ratio [OR] 6.8, 95% CI 0.7-64.5) and patients with provoked VTE (OR 5.54, 95% CI 0.6–
52.6) [20]. However, due to low case numbers and the cross-sectional study design, prospective 
cohort studies are needed. Only one recent prospective cohort study found that TSH levels below or 
above normal range were non-significantly associated with a moderately increased risk for VTE. 
However, this study was limited by the absence of free thyroxin (fT4) measurements, and could 
therefore not differentiate between overt and subclinical forms of thyroid dysfunction [21]. As no 
prospective data on SCTD and rVTE are currently available, we aimed to investigate a possible 
association between SCTD and rVTE as well as all-cause mortality in a large cohort of elderly 
patients with VTE. Our second objective was to evaluate whether patients with SCTD and an index 
VTE showed an increased thrombophilic risk profile compared to euthyroid patients.  
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Methods 
Cohort Sample: 
This study was conducted between September 2, 2009 and December 6, 2013 as part of the Swiss 
Cohort of Elderly Patients with Venous Thromboembolism (SWITCO65+), a prospective multicenter 
cohort study that assessed long-term medical outcomes in elderly patients with acute VTE from all 
five university and four high-volume non-university hospitals in Switzerland. As previously published 
in detail [22], participants aged ≥65 years with an acute, objectively confirmed VTE were 
prospectively identified in the in- and outpatient services of all participating study sites. Exclusion 
criteria were catheter-related thrombosis, insufficient German or French-speaking ability, no follow-
up possible (i.e., terminal illness), an inability to provide informed consent (i.e., severe dementia), or 
previous enrollment in the cohort. The study was approved by the Institutional Review Board at each 
participating center.  
From 1003 participants in the SWITCO65+ cohort study, we only considered those who had survived 
the first 12 months with a blood sample drawn at 12 months after the index VTE, since TSH/fT4 
levels may intermittently change due to an acute non-thyroidal illness [23-25], such as VTE. During 
the first year after baseline, 40 participants withdrew consent, 113 died and 1 was lost to follow-up. 
TSH and/or fT4 values were not available in another 274 participants 1 year after index VTE for 
various reasons (no permission by the participant, difficult venipuncture, unanalyzable blood tubes, 
laboratory error). After categorization into thyroid function groups, 3 participants with overt 
hyperthyroidism and 11 with overt hypothyroidism were excluded from analyses due to small 
numbers, leaving 561 participants for our study sample. 
Data collection: 
At baseline, demographic data, comorbidities and laboratory findings as well as VTE-related 
treatments of all enrolled patients were assessed according to a standardized data collection form by 
trained study nurses. Follow-up included two surveillance face-to-face evaluations and one telephone 
interview during the first year of study participation with subsequent semi-annual contacts, alternating 
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between face-to-face evaluations (clinic visits or home visits in house-bound patients) and telephone 
calls as well as periodic reviews of the patient’s hospital chart. During each visit/contact, study nurses 
interviewed patients to obtain information about the date and type of clinical events (recurrent VTE, 
death). If a clinical event had occurred, this information was complemented by reviewing medical 
charts and interviewing patients’ primary care physicians and family members. 
 
Clinical outcomes 
The primary clinical outcome was the recurrence of an objectively confirmed, symptomatic VTE 
(rVTE), defined as a fatal or new non-fatal PE, or a new DVT [8]. Diagnosis of rVTE during follow-
up was established based on  the following criteria: for DVT, on the basis of abnormal results on 
ultrasonography; and for pulmonary embolism, by means of CT or angiography showing new 
intraluminal defects or on the basis of ventilation-perfusion lung scan showing a high-probability 
pattern with new perfusion defects. A new proximal DVT, based on abnormal results on 
ultrasonography, associated with new PE symptom(s) (shortness of breath, chest pain, syncope) was 
considered as recurrent PE [26]. 
The secondary clinical outcome was incidence of all-cause mortality during follow-up. Deaths were 
adjudicated as related, possibly related, or unrelated to PE. Death was judged to be PE-related if 
confirmed by autopsy, or if death followed a clinically severe PE, either initially or after an 
objectively confirmed recurrent event. Death in a patient who died suddenly or unexpectedly was 
classified as possibly PE-related. Unrelated deaths were classified as a result of an obvious cause 
other than PE [27]. All clinical outcomes were adjudicated by a committee of three blinded clinical 
experts, and the final decision for diagnosis was based on full consensus. 
Laboratory measurements 
Blood samples were drawn at baseline (i.e., at the time of VTE diagnosis) and 1 year after index VTE 
(defining the start of observation time). Samples were immediately centrifuged, frozen, and stored in 
aliquots at -80°C and secondarily sent for analyses to a core laboratory. All analyses were performed 
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in study core laboratories and results were not communicated to the patients or their primary care 
physicians. Specific information about blood collection, storage and laboratory analysis is described 
elsewhere [28]. 
Thyroid status was assessed by analyzing serum TSH and fT4 in frozen aliquots in 2014. Thyroid 
hormone levels were determined by using state-of-the art TSH- and fT4-specific immunoassays 
named ElectroChemiLuminescence ImmunoAssay (ECLIA, Roche) on a Roche Modular E170 
device.  
In line with previous large studies [19], euthyroidism was defined as TSH levels between 0.45 and 
4.49 mIU/L, SHypo as TSH levels between 4.5 and 19.9 mIU/L, and SHyper as TSH smaller than 
0.45 mIU/L , both with fT4 values within normal range (12-22.0 pmol/l). 
For the cross-sectional analyses of thrombophilic biomarkers by thyroid status, we included the 
following laboratory measurements based on previously studied associations with rVTE and/or 
thyroid dysfunction: D-dimer, measured by an immunoenzymatic assay on a Vidas Biomerieux 
automated system [29]; fibrinogen, levels of antithrombin, protein C, free protein S, FVIII, FIX, FXI 
and vWF:Ag on a BCS XP Siemens device [12, 13, 17, 30]; fasting homocysteine level was 
quantified using an automated high performance liquid chromatography (HPLC) with reverse phase 
separation and fluorescent detection after the derivation step (with 7-Fluorobenzofurazane-4-
sulfonique acid) on a HPLC 1100 from Agilent Technologies. 
Participants on oral anticoagulants were excluded from the analyses of Vitamin-K dependent factors, 
such as FIX and Protein S [31]. 
 
Statistical analyses 
We compared baseline characteristics and biomarker levels among participant groups with different 
thyroid function using chi-squared tests and non-parametric Kruskal-Wallis rank tests as appropriate. 
We present the cumulative incidence of rVTE accounting for non-PE related death as a competing 
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risk using the method of Coviello and Boggess [32]. For mortality, we present ordinary Kaplan-Meier 
curves. We calculated incidence rates of a first rVTE and mortality rates for different thyroid function 
groups and compared survival functions using log-rank tests.  
Associations of thyroid function groups and log-transformed TSH values with the time to a first rVTE 
were examined using competing risk regression according to Fine and Gray [33], accounting for non-
PE-related death as a competing event. The method yields sub-hazard ratios (SHR) with 
corresponding 95% CIs and p values for the failure event of primary interest. We repeated these 
analyses using cause-specific Cox proportional hazard regression with robust standard errors. For 
mortality, an ordinary cause-specific Cox-regression with robust standard errors was calculated. In 
case of no events in a subgroup, we obtained confidence intervals using the profile likelihood method. 
In order to avoid overfitting in regard to 52 rVTE and 56 death events during observation time, we 
performed multivariate models with minimal adjustment, adjusting for  (1) age and gender, (2) age, 
gender and rVTE risk factors including: prior VTE [34], active cancer [35], idiopathic VTE [30] and 
periods of anticoagulation as a time-varying covariate [8], (3) additionally log-transformed fibrinogen, 
since it has been previously discussed as a mediator between subclinical hyperthyroidism and VTE 
[36]. There were no missing values in variables of the main analyses (crude and adjusted associations 
of thyroid function groups and log-transformed TSH values with the time to a first rVTE). 
As described above, we started observation time 12 months after index VTE, but conducted 
sensitivity analyses with: 1) observation time starting at the index VTE; 2) excluding patients with 
rVTE within 4 weeks before the 1-year blood samples; 3) observation time lasting for 12 months after 
TSH/fT4 analyses. In order to investigate associations between thrombophilic biomarkers and thyroid 
status, we compared mean serum levels using analysis of variance (ANOVA) and analysis of 
covariance (ANCOVA). For this analysis, levels of D-dimer, fibrinogen, protein S, homocysteine, and 
FVIII were log-transformed due to their skewed, log-normal distribution (Supplementary Table 2). 
Levels of protein C could not be normalized due to its U-shaped and censored distribution and were  
thus evaluated non-parametrically using a Kruskal-Wallis rank test. In ANCOVA, minimal 
adjustment was done for age and gender, full adjustment for age, gender and factors known to be 
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associated with thrombophilic states, namely smoking status [37], active cancer [38] and diabetes 
mellitus [39]. There were only a few missing values in thrombophilic biomarkers. We therefore 
followed a complete case analysis when adjusting for fibrinogen and evaluating thrombophilic 
biomarkers. All analyses were done using Stata 14 (Stata Corporation, College Station, Texas). 
This study is an ancillary study of the SWITCO65+ cohort study, which was powered in order to 
detect a ≥2-fold risk increase of VTE recurrence in patients with compared to patients without a risk 
factor if the prevalence of the risk factor is at least 10% [22]. 
 
Results 
Participants 
Baseline characteristics are presented in Table 1. Overall, 35 participants (6%) had SHypo, 500 (89%) 
were euthyroid and 26 (5%) had SHyper. The median TSH level for the entire study population was 
1.9 mIU/l (interquartile range 1.2-2.7) with 2 patients showing a TSH≥10 mIU/l. At 12 months after 
the index VTE, 326 patients (58%) were still receiving anticoagulant treatment, in most instances 
vitamin K antagonists (56%). The distribution or quality of anticoagulant therapy did not significantly 
differ at the time of thyroid hormone measurements (Table 1). 
 
Participants with SHyper were more likely to be female and immobilized than SHypo and euthyroid 
participants. Non-analyzed patients were generally older (76 years, interquartile range [IQR]: 71.0–
83.0 vs. 74 years, IQR 69.0-80.0, p<0.01), suffered more frequently from cardiovascular diseases (3% 
vs. 1%, p=0.02), active cancer (27% vs 11%, p<0.01), as well as immobilization (26% vs. 19%, 
p<0.01), and comprised more women (55% vs. 41%, p<0.01) than analyzed participants 
(Supplementary Table 1). 
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Association between Thyroid Status and rVTE 
After a mean follow-up of 20.8 months (standard deviation ± 9.1) starting one year after index VTE, 
52 (9.2%) participants had experienced a rVTE, thereof 87% were off anticoagulation. rVTE 
incidence rates were 7.20 per 100 patient-years (95% CI 2.70–19.19) among participants with SHypo 
vs. 5.85 per 100 patient-years (95% CI 4.41–7.77) in euthyroid controls, whereas no event occurred 
among participants with SHyper (Table 2).  
In multivariate competing risk analyses, SHyper was significantly associated with lower rVTE (Table 
2). When adjusting for age and gender, participants with SHyper had a SHR of 0.00 (95% CI 0.00-
0.63, p=0.01), whereas those with SHypo had a sub-hazard ratio [SHR] of 1.23 for rVTE (95% CI 
0.42-3.67, p=0.70), compared to euthyroid controls. After further adjustment for known rVTE risk 
factors, the association between SHyper and rVTE remained significant (Table 2). TSH as a 
continuous variable was not associated with rVTE (adjusted SHR per log-unit increase: 1.18, 95% CI 
0.87–1.60, p=0.28, Table 3). Additional adjustment for fibrinogen, a possible mediator between 
thyroid function and VTE, yielded fairly the same results. In a sensitivity analysis observing 
recurrence rate from the time of the index VTE, the SHR was 0.20 (95% CI 0.03–1.56, p=0.13) for 
SHyper and 1.15 (95% CI 0.45–2.93, p=0.77) for SHypo, as compared to euthyroid controls. 
Analyses according to TSH quartiles showed no difference in rVTE incidence (p=0.98). Considering 
the higher rVTE incidence rate in SHypo vs. euthyroidism during the first year (Figure 1, 13.27 vs. 
6.56 per 100 patient-years, respectively), we performed a secondary analysis with an observation time 
limited to the first 12 months after thyroid hormone measurements and found a HR of 2.50 (95% CI 
0.89-7.00, p=0.08) for the association between SHypo and rVTE, as compared to euthyroid 
participants. Overall, we obtained similar results using Cox regression for the cause specific hazards. 
Association between Thyroid Status and Thrombophilic Biomarkers  
The vWF antigen was the sole thrombophilic biomarker which significantly differed between thyroid 
groups in crude ANOVA (p<0.01), as well as in age-and sex-adjusted ANCOVA (p=0.03), but this 
association was weaker after fully adjusted ANCOVA (p=0.05, Table 4). The highest mean plasma 
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concentration was found in SHyper (243%, 95% CI 186-301), followed by subclinically hypothyroid 
(213%, 95% CI 191-235) and euthyroid (198%, 95% CI 192-205) participants, but differences were 
only statistically significant between those with SHyper and euthyroidism (p=0.02; SHypo vs 
euthyroids: p=0.32). Likewise, the FVIII/vWF:Ag ratio varied significantly between SHypo, SHyper 
and euthyroidism, but after adjusting for smoking, diabetes mellitus and active cancer, it was only 
significantly different for SHyper compared to euthyroids (p=0.04; SHypo vs euthyroid: p=0.18). 
Median and interquartile ranges of thrombophilic biomarker levels by thyroid status are presented in 
Supplementary Table 2. 
Mortality by Thyroid Status 
During a mean observation time of 20.8 months, 56 (10.0%) participants died. Mortality did not differ 
by thyroid status (Figure 2). The highest mortality was observed in participants with SHyper (6.2 per 
100 patient-years, 95% CI 2.0-19.2) followed by euthyroids (5.8 per 100 patient-years, 95% CI 4.4-
7.7) and participants with SHypo (5.1 per 100 patient-years, 95% CI 1.6–15.8). Thyroid status and 
TSH as continuous variable were not associated with mortality in multivariate models (Tables 2, 3).   
Discussion:  
In this prospective multicenter cohort study of elderly VTE patients, SHyper was associated with a 
lower rVTE risk. On the other hand, SHypo was not significantly associated with an increased rVTE 
risk, although there was a pattern thereof, particularly during the first year of follow-up. Moreover, 
SCTD was neither associated with mortality nor increased levels of several thrombophilic biomarkers, 
except for vWF:Ag which was borderline significantly increased in SHyper. 
Data on SCTD and VTE are limited. A recently published prospective cohort study on 11,900 subjects 
aged 25-89 years [21] found a non-significantly increased risk for rVTE among both patients with 
elevated and decreased TSH values compared to healthy controls (HRs: 1.55, 95% CI 0.87-2.77 and 
2.16, 95% CI 0.69-6.76, respectively). Results of this previous study were limited by the absence of 
fT4 measurements, so that the authors could not discriminate between overt and subclinical forms of 
thyroid dysfunction, and confidence intervals were rather wide. In contrast to these findings, we found 
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a potentially lower rVTE risk in SHyper vs. euthyroids. Squizzato et al. [20] investigated the 
association between DVT and SHypo/SHyper in a pilot case-control study of 150 patients, comparing 
groups with unprovoked DVT, provoked DVT and healthy controls. The prevalence of SHypo was 
higher (OR 5.54; 95% CI: 0.6-52.6) in patients with unprovoked DVT (14.0%), as compared to 
healthy subjects (2%) and those with provoked DVT (1%), but results were limited by the cross-
sectional design, large confidence intervals. Furthermore, we could not corroborate the hypothesis of 
a hypercoagulable or hypofibrinolytic state in those patients in our analysis of thrombophilic 
biomarkers. In comparison, the present prospective cohort included also PE and was 3 to 4-fold 
greater in sample size.  
Previous findings on thrombophilic biomarkers in SCTD were mostly obtained from case-control 
studies with low sample sizes (i.e. 65 to 156 patients) [17, 36] and thus may be subject to substantial 
selection bias. In our large prospective study, we found no increase in most thrombophilic biomarkers 
among participants with SCTD compared to euthyroid controls. For example, we did not detect an 
increased concentration of fibrinogen in contrast to previous studies [40]. Moreover, D-dimer levels 
resulted to be fairly the same across all thyroid function groups (p=0.98). These findings do not 
support the concept of a hypercoagulable state, and an increased or decreased fibrinolysis in 
participants with SCTD. We generally observed increased vWF:Ag concentrations, whereas SHyper, 
but not SHypo participants had significantly higher vWF:Ag levels than euthyroid controls. Similarly, 
the association between vWF:Ag levels and SHyper has previously been shown in a meta-analysis of 
observational studies among patients with SHyper and overt hyperthyroidism (standardized mean 
difference, i.e. the difference between the group means divided by the pooled standard deviation: 2.9, 
95% CI 1.4-3.3) compared to euthyroids [12]. In line with our findings, a case-control study found 
higher mean concentrations of vWF in SHyper than in controls (111.8 vs. 94.2 ng/ml) but this 
difference was not statistically significant [36]. The pathogenic role of vWF as a thrombophilic risk 
factor has been studied in knock-out mice models [41]. However, there are conflicting data regarding 
the role of vWF in the development of VTE in humans, independently from increased FVIII 
concentrations [42, 43]. In our analyses, FVIII concentrations were within normal range and an 
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increased FVIII/vWF ratio as an indicator for higher levels of unbound FVIII [44] could not be 
demonstrated.  
Our study has several strengths. First, to our knowledge, this is the first prospective cohort study 
investigating the relationship between SCTD and rVTE. Second, rVTE was adjudicated by a blinded 
expert committee using clearly defined objective criteria, reducing the risk of detection bias. Finally, 
both in- and outpatients with index VTE were included in a nationwide multicenter setting, leading to 
an increased generalizability.  
On the other hand, there were several limitations. First, there were relatively few participants and 
rVTE events in the SHypo and SHyper group, leading to rather wide confidence intervals. The 
Kaplan-Meier curves and multivariate analyses indicated that patients with SHypo had an increased 
risk of rVTE, but confidence intervals of sub-hazard ratios were rather wide and associations not 
statistically significant. Although we could identify a significant association between SHyper and a 
lower rVTE risk in our cohort, caution should be taken before definitive conclusion, because patient 
numbers were low for SHyper and a possible chance-finding cannot be excluded. However, 
prevalence of SHyper was higher in the present cohort (5%) compared to 0.7- 3.2% described in 
literature [10]. Second, we planned to investigate a dose-dependent effect of TSH on rVTE risk in 
stratified analyses, including assessment of the impact of higher TSH concentrations, but these 
analyses could not be performed owing to no rVTE event in this subgroup of only 2 participants with 
TSH between 10-19.9 mIU/l. Consistently, stratified analyses for provoked/unprovoked index VTE 
and its subtypes could not be performed due to few vs. no rVTE events in SHypo vs. SHyper, 
respectively. Third, any acute non-thyroidal illness [23-25], such as VTE and related radiologic 
procedures involving iodinated contrast media [45], may temporarily influence thyroid function. 
Therefore, we measured thyroid hormones 1 year after the index VTE and obtained comparable 
results from a sensitivity analysis excluding participants with rVTE within one month before blood 
sampling.  Since our observation time started 12 months after the index VTE, we could not assess the 
association between SCTD and short-term risk of rVTE.  
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Fourth, the SWITCO65+ study was not specifically designed for thyroid disease. Thus, history of 
thyroid disease or change in thyroid status were not assessed. SHypo has an annual rate of 3-4.3% for 
spontaneous progression to overt thyroid dysfunction [46], whereas 15 to 62% revert to euthyroidism 
over follow-up periods of one to six years [47]. SHyper similarly progresses to overt disease in 1-2% 
of affected individuals per year [48]. Finally, as thyroid hormone measurements were retrospectively 
obtained from the SWITCO65+ biobank, information on thyroid medication use was not available and 
we could not exclude those patients, which may have decreased the association between SHypo and 
rVTE. As laboratory results were neither communicated to participants nor to treating physicians due 
to unclear evidence for benefit of treatment, new prescription of thyroid medication was likely low 
during follow-up; based on a survey at the two largest study sites (Bern, Lausanne), only 3 patients 
with SHypo received thyroid hormone replacement therapy until the end of follow-up.  According to 
previous prospective cohorts on SCTD, the incidence of new thyroid drug users ranged between 0% 
to 3.3% in studies with mean follow-up durations of 2 to 5 years [19]. Despite a higher incidence rate 
of rVTE among SHypo vs. euthyroidism in the first 1 year after TSH measurement (Figure 1), we did 
not find an initially significant association with rVTE, which may have been washed out by newly 
prescribed thyroid replacement therapy during follow-up.  
Conclusions 
In this prospective multicenter cohort study, SHyper was associated with a decreased recurrence risk 
in elderly VTE patients. SHypo showed a non-statistically significant pattern of an association with 
rVTE, especially in the first year of follow-up. SCTD was neither associated with mortality nor 
increased levels of several thrombophilic biomarkers, except for vWF:Ag which was borderline 
significantly increased in SHyper. 
Future research projects should verify our results, particularly in younger populations (requiring larger 
study samples or longer observation times), and additionally assess a possible dose-dependent effect 
of TSH on coagulation parameters and clinical outcomes, which would need larger cohort studies with 
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a higher prevalence of SHypo. Finally, to definitively prove a causal relationship between thyroid 
replacement therapy and rVTE, randomized controlled trials would be needed.  
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Tables  
Table 1: Patient Characteristics 
 
All 
Subclinical 
hypothyroidism      
TSH 4.50-19.99 
mIU/l, normal fT4 
Euthyroidism                       
TSH 0.45-4.49 
mIU/l, normal fT4  
Subclinical 
hyperthyroidism       
TSH<0.45 mIU/l, 
normal fT4 
p 
Total N 561 (100%) 35 (6%) 500 (89%) 26 (5%) 
 
Demographics            
Gender (female) 229 (41%) 14 (40%) 196 (39%) 19 (73%) 0.003 
Age, years 74 (69.0; 80.0) 75.0 (69.0; 81.0) 74.0 (68.0; 79.0) 79.0 (73.3; 84.3) 0.059 
Clinical characteristics 
     
Obesity (BMI ≥30 kg/m
2
) 152 (27%) 11  (31%) 133  (27%) 8 (31%) 0.751 
Diabetes mellitus  93 (17%) 8 (23%) 80 (16%) 5 (19%) 0.535 
Arterial hypertension 364 (65%) 25 (71%) 319 (64%) 20 (77%) 0.277 
History of cardiovascular and cerebrovascular 
disease a 
6 (1%) 0 (0%) 5 (1%) 1 (4%) 0.317 
Current smoking 39 (7%) 1 (3%) 37 (7%) 1 (4%) 0.482 
Active cancer b  63 (11%) 2 (6%) 57 (11%) 4 (15%) 0.465 
Immobilization b 104 (19%) 5 (14%) 88 (18%) 11 (42%) 0.005 
Oestrogen replacement therapy b 16 (3%) 2 (6%) 13 (3%) 1 (4%) 0.537 
Prior VTE  166 (30%) 18 (51%) 139 (28%) 9 (35%) 0.011 
Postthrombotic syndrome * 201 (36%) 14 (40%) 173 (35%) 14 (54%) 0.119 
Any acute rheumatic disease b 22 (4%) 1 (3%) 19 (4%)   2 (8%) 0.575 
Inflammatory bowel disease 20 (4%) 0 (0%) 20 (4%) 0 (0%) 0.282 
History of major surgery b 87 (16%) 4 (11%) 75 (15%) 8 (31%) 0.076 
Anticoagulation at the time of index VTE 
     
Initial anticoagulation 558 (99%)     35 (100%)     498 (100%)     25 (96%)      0.057  
Initial anticoagulation < 3 months 48 (9%)     2 (6%)      40 (8%)     6 (23%)      0.023  
Parenteral anticoagulation 544 (97%) 35 (100%) 484 (97%) 25 (96%) 0.548 
Oral anticoagulation 522 (93%) 34 (97%) 467 (93%) 21 (81%) 0.029 
Concomitant antiplatelet therapy 177 (32%) 11 (31%) 158 (32%) 8 (31%) 0.996 
Percent time in therapeutic range (between 
index VTE and time of thyroid hormone 
measurements) 
65.3 (47.2; 80.9) 55.9 (37.9; 74.5) 66.8 (47.7; 81.2) 55.2 (38.7; 65.7) 0.048 
Duration of initial anticoagulation (months) 11.1 (5.9; 29.7) 23.2 (6.4; 30.5) 10.1 (5.9; 29.6)   6.7 (3.2; 29.8) 0.214 
Anticoagulation at the time of thyroid 
hormone measurements * 
     
Any anticoagulation 326 (58%)  23 (66%)      289 (58%) 14 (54%) 0.593 
Parenteral anticoagulation 20 (4%) 0 (0%) 19 (4%) 1 (4%) 0.502 
Oral anticoagulation  314 (56%) 23 (66%) 277 (55%) 15 (54%) 0.481 
Percent time in therapeutic  range (between 
thyroid hormone measurement and 1 year 
thereafter) 
71.1 (53.7; 88.1) 69.2 (47.2; 83.4) 72.5 (55.1; 89.1) 50.9 (26.7; 88.3) 0.100  
      
Variables recorded at the time of index venous thromboembolic event (VTE), if not otherwise indicated.  
Values given as total number (N, %) or median (interquartile range). BMI= Body Mass Index; p= p-value 
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There were missing values in fibrinogen (7%) and hsCRP (7%). 
a  defined as patient-reported myocardial infarction/stroke during the last 3 months  
b within 3 months before index VTE. 
* Variables recorded at the time of thyroid hormone measurement 1 year after index VTE 
 
 
Table 2:  
Association of Thyroid Status with Recurrent Venous Thromboembolisms (VTE) and All-Cause 
Mortality  
  
Subclinical 
hypothyroidism TSH  
4.50 - 19.99 mIU/l, 
normal fT4 
p  
Euthyroidism   
TSH 0.45 - 4.49 
mIU/l, normal fT4 
p  
Subclinical 
hyperthyroidism TSH < 
0.45 mIU/l, normal fT4 
Overall 
p 
Total N 35 (6%)   500 (89%)   26 (5%)  
Recurrent VTE            
Number of events/person-years 4/55.5 
 
48/820.1 
 
0/48.4  
Incidence rate per 100 person-years 
(95% CI) 
7.20 (2.70 -  19.19) 
 
5.85 (4.41 - 7.77) 
 
0.00 (0.00 - 7.63)*  
Crude SHR (95% CI) 1.24 (0.43 -  3.57) 0.70 reference  0.02 0.00 (0.00 – 0.71)a 0.06 
Age-and sex-adjusted SHR (95% CI) 1.23 (0.42 - 3.67) 0.70 reference  0.01 0.00 (0.00 – 0.63)a 0.04 
Multivariate-adjusted SHR (95% CI)b 1.50 (0.52 - 4.34) 0.46 reference  0.01 0.00 (0.00 – 0.58)a 0.02 
Fibrinogen-adjusted SHR (95% CI)c 1.49 (0.51 - 4.33) 0.46 reference  0.01 0.00 (0.00 – 0.57)a 0.02 
All-cause mortality            
Number of events/person-years 3/59.0 
 
50/862.8 
 
3/48.4  
Incidence rate per 100 person-years 
(95% CI) 
5.08 (1.64 - 15.76) 
 
5.80 (4.39 - 7.65) 
 
6.20 (2.00 - 19.23)  
Crude HR (95% CI) 0.87 (0.27 - 2.84) 0.82 reference  0.91 1.08 (0.32 - 3.63) 0.96 
Age-and sex-adjusted HR (95% CI) 0.77 (0.23 - 2.60) 0.67 reference  0.98 0.98 (0.29 - 3.35) 0.90 
Multivariate-adjusted HR (95% CI)b 0.99 (0.30 - 3.29) 0.98 reference  0.73 0.80 (0.23 - 2.81) 0.93 
Fibrinogen-adjusted HR (95% CI)c 0.88 (0.27 - 2.86) 0.83 reference  0.90 0.92 (0.26 - 3.31) 0.91 
 
Sub-hazard and hazard ratios (SHR and HR) and incidence rates given with 95% confidence interval (95% CI). The overall 
p-value is from a likelihood ratio test.  p = p-value. VTE: venous thromboembolism defined as any event of deep vein 
thrombosis and/or pulmonary embolism 
 a Confidence intervals from profile-likelihood method and p-value from likelihood-ratio test in case of zero events. 
b adjusted for age, sex, prior VTE, active cancer, idiopathic VTE, and periods of anticoagulation as a time-varying covariate.  
c adjusted for fibrinogen as continuous log-transformed variable, age, sex, prior VTE, active cancer, idiopathic VTE, and 
periods of anticoagulation as a time-varying covariate. 
* Exact confidence interval based on a Poisson distribution 
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Table 3: 
Association of Log-transformed TSH with Recurrent Venous Thromboembolisms (VTE) and 
All-Cause Mortality  
  n/N  SHR or HR (95% CI) p 
Recurrent VTE        
Crude  (95% CI) 52/561 1.10 (0.84-1.45) 0.48 
Age-and sex-adjusted  (95% CI) 52/561 1.13 (0.85-1.51) 0.39 
Multivariate-adjusted  (95% CI)a 52/561 1.18 (0.87-1.60) 0.28 
Fibrinogen adjusted  (95% CI)b 52/558 1.19 (0.87-1.61) 0.28 
All-cause-mortality       
Crude  (95% CI) 56/561 0.83 (0.64-1.08) 0.17 
Age-and sex-adjusted  (95% CI) 56/561 0.84 (0.64-1.11) 0.22 
Multivariate-adjusted  (95% CI)a 56/561 0.88 (0.66-1.18) 0.41 
Fibrinogen-adjusted  (95% CI)b 56/558 0.85 (0.64-1.14) 0.28 
 
N: number of patients, n: number of events, HR: hazard ratio, SHR: sub-hazard ratio, CI: confidence interval, p= p-value.   
SHR and HR are expressed per one log-unit increase. VTE: venous thromboembolism defined as any event of deep vein 
thrombosis and/or pulmonary embolism 
a adjusted for age, sex, prior VTE, active cancer, idiopathic VTE, and periods of anticoagulation as a time-varying covariate.  
b adjusted for fibrinogen as continuous log-transformed variable, age, sex, prior VTE, active cancer, idiopathic VTE, and 
periods of anticoagulation as a time-varying covariate. 
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Table 4:  
Association between Thrombophilic Biomarkers and Thyroid Status 1 year after index VTE  
  
Subclinical 
hypothyroidism            
TSH 4.5-19.99 mIU/l, 
normal fT4   
Euthyroidism                       
TSH 0.45-4.49 mIU/l, 
normal fT4 
Subclinical 
hyperthyroidism       
TSH<0.45 mIU/l,  
normal fT4  
p             1st 
adjustment  
p           2nd 
adjustment 
vWF:Ag (%) 
213                   (191-
235) 
198                 (192-
205) 
243                   (186-
301) 
0.03 0.05 a 
D-dimer § 
6.60                       
(6.31-6.89) 
6.54                         
(6.47-6.61) 
6.71                            
(6.46-6.96) 
0.97 0.98 
Fibrinogen § 
1.26                        
(1.19-1.34) 
1.21                              
(1.19-1.23) 
1.24                             
(1.14-1.34) 
0.55 0.52 
Protein S § # 
4.59                        
(4.46-4.72) 
4.48                             
(4.45-4.52) 
4.57                             
(4.52-4.63) 
0.13 0.17 
Antithrombin (%) 
101                     (95-
106) 
101                         
(99-102) 
104                         (98-
110) 
0.85 0.89 
Homocysteine § 
2.73                           
(2.61-2.85) 
2.64                            
(2.60-2.68) 
2.61                               
(2.43-2.78) 
0.59 0.59 
Factor VIII § 
5.00                              
(4.90-5.10) 
5.00                             
(4.97-5.03) 
4.91                                  
(4.78-5.04) 
0.19 0.15 
Factor IX (%) # 
128                         
(123-133) 
117                           
(115-119) 
115                         
(101-130) 
0.26 0.28 
Factor XI (%) 
110                   (105-
116) 
108                   (106-
109) 
115                     (105-
124) 
0.32 0.38 
Factor VIII/ vWF:Ag  
ratio 
0.77                    (0.69-
0.85) 
0.84                    
(0.81-0.86) 
0.71                     (0.58 
- 0.84) 
0.04 0.05 b 
 
There were missing values in fibrinogen (7%) and hsCRP (7%). Missingness for other variables was below 1%. 
Values given as means and 95% confidence interval. p= p-value,  vWF:Ag: von Willebrand  factor antigen; VTE: venous 
thromboembolism defined as any event of deep vein thrombosis and/or pulmonary embolism. § log-transformed for 
ANOVA/ANCOVA analysis due to skewed log-normal distribution; # Participants on oral anticoagulants were excluded 
from these analyses.  
 
 
1st adjustment: adjusting for age and gender, 2nd adjustment: further adjusting for smoking status, active cancer, diabetes 
mellitus 
a Pairwise p-values from ANCOVA analyses after 2nd adjustment for  vWF:Ag: 
subclinical hyperthyroidism vs. euthyroidism, p=0.02, subclinical hypothyroidism vs. euthyroidism, p=0.32 
 
b Pairwise p-values from ANCOVA analyses after 2nd adjustment for FVIII/ vWF:Ag ratio: 
subclinical hyperthyroidism vs. euthyroidism, p=0.04, subclinical hypothyroidism vs. euthyroidism, p=0.18 
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